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n-3 fatty acids reduce proteinuria in patients with chronic glomerular
disease. Dietary supplementation with n-3 polyunsaturated fatty acids
(n-3 PUFA) has been shown to reduce proteinuria in experimental
models of renal diseases, but their potential role in the treatment of
human renal disease is unknown. We administered n-3 PUFA in the
form of triglycerides [with eicosapentenoic (EPA) + docosahexaenoic
(DHA) = 3 glday into 4 patients] and of ethyl esters (EPA + DHA = 7.7
g/day) into 10 patients (one patient twice) with chronic glomerular
disease (membranous glomerulonephritis and focal glomerular sclero-
sis), all diagnosed histologically. Serum albumin was >2.4 gIdl and
serum creatinine <2.5 mgldl in all patients. Treatment was given for
periods of six weeks, followed by a prolonged follow-up for 27 weeks in
10 cases. Dietary supplementation with n-3 PUFA caused the expected
reduction in platelet generation of thromboxane 82 (mean SEM, from
490 70 ng/ml at baseline, to 342 147 ng/ml at 6 weeks, P < 0.05) of
serum triglycerides (from 236 60 to 170 43, P < 0.01), and a
prolongation of the bleeding time (from 5.8 0.4 mm to 7.7 0.4 mm,
P < 0.01) in patients treated with ethyl esters. A modest but significant
reduction in serum total cholesterol was noticed (from 275 27 to 252
24 mgldl). Urinary thromboxane B2 excretion (as a reflection of renal
TXA2 production) and urinary 6-keto-PGF1,, excretion (as a reflection
of renal PGI2 production), assayed by extraction, chromatographic
separation and RIA with antibodies cross-reacting with metabolites of
the n-3 series, were both similarly reduced by the ethyl ester treatment
(for TXB2: 7.8 1.7 ng/hr at week 0; 4,2 0.6 ng/hr at week 6, P =
0.06; for 6-keto-PGF1,: 24.4 5.1 ng/hr at week 0; 16.4 2.9 ng/hr at
week 6, P = 0.09). Serum albumin, creatinine and creatinine clearance
did not change significantly throughout the study. The high dose
regimen, however, caused a significant reduction in proteinuria (from
3.7 1.0 g/24 hr at week 0 to 2.6 0.7 g/24 hrat week 6, P <0.05). This
was sustained at weeks 10 and 16 and returned to baseline values at
week 27. A modest reduction in blood pressure was also noticed, but it
did not correlate with the change in proteinuria. Thus, n-3 PUFA may
have a therapeutic role in reducing proteinuria in patients with chronic
glomerular disease. The relationship of modifications in renal ei-
cosanoids with this effect is uncertain.
There has been considerable recent interest about the effects
of n-3 polyunsaturated fatty acids (n-3 PUFA) in human phys-
iology and human diseases [1, 2]. Dietary supplementation with
these fatty acids leads to a number of biological changes. These
include effects on plasma lipids and lipoproteins [3], eicosanoid
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metabolism [4—7], platelet-vessel wall interactions [8], blood
viscosity [9], arterial blood pressure [10—12], coagulation [13],
cytokines [14, 15], and growth factors [16]. Most of these
changes are of potential therapeutic benefit to patients with
renal disease, either by ameliorating kidney function or slowing
the progression of chronic renal failure.
Animal models of both inflammatory renal diseases [17—241
and reduced renal mass [25—29] mostly show improvement of
kidney function following administration of n-3 fatty acids.
However, to date there has been little focus on the potential
application of these substances in a clinical framework, Reports
have appeared for use in transplantation patients to limit
cyclosporine-induced nephrotoxicity [30, 31], in lupus nephritis
[321 and IgA nephropathy [33—35]. We therefore decided to
investigate the effects of n-3 PUFA administration in human
chronic glomerular disease, an important cause of chronic renal
failure and for which no satisfactory conservative therapy is
known.
Methods
Patients
Between December 1989 and March 1992, all patients admit-
ted to the Nephrology Division of Spedali Riuniti di Santa
Chiara in Pisa, Italy were included if they met the following
criteria: (a) membranous or membrano-proliferative glomerulo-
nephritis or idiopathic focal glomerular sclerosis characterized
by renal biopsy within the previous six months; (b) albumine-
mia >2.4 g/dl; (c) serum creatinine <2.5 mgldl. Exclusion
criteria were: (1) intake of steroidal or non-steroidal anti-
inflammatory agents, antiplatelet agents or anticoagulants; and
(2) acute or subacute liver or pancreas disease. All patients
were chronically on a low-sodium diet (2 glday of sodium
chloride were provided to patients to be distributed at patient's
will throughout the meals). No other medical therapy was
allowed, with the exception of antihypertensive therapy (nitren-
dipine), given to one patient (MM) chronically, and never
altered throughout the study.
Protocol approval was obtained by an Internal Review Board
and patients' consent was obtained in all cases. Ten patients
were recruited: three of them were studied twice (Study A and
B), and one patient was studied three times (once on Treatment
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Table 1. Clinical and baseline laboratory data of patients
Patient initials Sex
Age
years
Weight
kg
Height
cm Histologic diagnosis
Baseline
Albumin
g/dl
Creatinine
mg/dI
Creatinine
clearance
mi/mm
n-3 triglyceride study
VP
LM
MM
PMR
M
M
M
F
56
70
39
28
67
55
73
64
162
170
180
162
membranous ON
membranous GN
focal OS
focalGS
3.0
2.6
3.9
4.2
1.1
1.0
1.2
0.6
89
80
114
105
n-3 ethyl ester study
VP
LM
MM
MM-Il
PMR
BS
LA
OA
BM
DO
CE
M
M
M
M
F
M
F
M
M
F
F
56
70
39
39
28
27
41
43
22
38
43
67
55
73
73
64
91
55
77
91
62
79
162
170
180
180
162
176
160
172
187
160
161
membranous ON
membranous ON
focal OS
focal OS
focal OS
focal OS
focal GS
membranous GN
focal OS
focal OS
focalGS
2.4
2.8
3.9
4.0
3.9
3,9
2.5
2.5
3.3
3.7
3.4
0.9
1.0
1.4
1.5
0.6
1.4
0.6
1.8
1.2
0.5
0.7
80
73
87
64
108
90
155
50
148
125
120
Pt. MM underwent two cycles with the ethyl ester preparation. Abbreviations are: ON, glomerulonephritis; GS, glomerulosclerosis.
A and twice on Treatment B). Patients' characteristics are listed
in Table 1.
Study design
This was a prospective, open-label study. Patients recei\ ed
trial medications from week 0 to week 6, and were followed-up
at weeks 10 and 16 after discontinuation of trial medication. In
nine cases (3 on Treatment A and 6 on treatment B) a prolonged
follow-up at week 27 was available, Long follow-up periods
after discontinuation of trial treatment were chosen due to past
observations of long-lasting carry-over effects of n-3 PUFAs
[14, 15J.
Trial treatments were: for treatment A, MaxEPA (provided
by Fresenius, Bad Homburg, Germany), capsules of triglycer-
ides of n-3 PUFA, each containing 750 mg of fish oil, yielding
33% of eicosapentaenoic acid (EPA) + docosahexaenoic acid
(DHA), given as 12 capsules/day, with meals, for a total amount
of n-3 PUFA supplementation of about 3 g!day; for treatment B,
K-85 (provided through Fresenius), capsules of ethyl-esters of
n-3 PUFA, each containing 1000 mg of fish oil, yielding 85% of
EPA + DHA, given as 9 capsules/day, with meals, for a total
amount of n-3 PUFA supplementation of 7.7 g/day.
Thus, treatment A was a low-dose regimen of 3 g n-3 PUFAs
daily and treatment B a high dose regimen of 7.7 g n-3 PUFAs
daily.
Patients were advised not to change their usual dietary
habits, including remaining on a low-salt diet (approximately 2
g of NaC1 supplement to be distributed, at patient's will,
throughout the meals) and not altering the usual protein intake.
This last point, specifically, was objectively monitored by
measurements of urinary nitrogen excretion (see below).
Laboratory and clinical analyses included the following as-
says:
Incorporation of n-3 PUFAs into plasma lipids was evaluated
through the analysis by gas liquid chromatography of fatty acids
in plasma total lipids after preparation of methyl ester deriva-
tives. After acidic transmethylation, fatty acid methyl esters
were separated on a Dani GC-85.l0 gas chromatograph
equipped with a 30 m Supelco Omegawax capillary column
(0.32 mm I.D., 0.25 m film thickness) and a flame ionization
detector. A discontinuous temperature gradient from 130 to
220°C was used. The H2, air and carrier (helium) pressures were
0.8, 0.9 to 1, and 0.6 bar, respectively. Individual peaks were
integrated automatically using a Shimadzu C-R6A Chromato-
pac integrator.
Serum triglycerides and total serum cholesterol were mea-
sured by enzymatic colorimetric methods (GDP-PAP and
Monotest cholesterol CHOD-PAP, respectively, Boehringer-
Mannheim, Mannheim, Germany). High-density lipoprotein
(HDL) cholesterol was measured in the supernatant after pre-
cipitation of apolipoprotein B-containing lipoproteins with
MgCl2 by a similar enzymatic colorimetric method (Carlo Erba,
Milan, Italy).
Bleeding time was measured according to Mielke's modifica-
tion of the method of Ivy, using a disposable device (Surgicutt,
Ortho Diagnostics, Raritan, New Jersey, USA) and a trans-
verse incision on the lateral aspect of the volar surface of the
forearm and mantaining venous pressure at 40 mm Hg by the
inflation of a sphygmomanometric cuff.
Serum thromboxane B2 (TXB2) was measured in clotted
blood prepared by placing duplicate 1 ml samples of freshly
drawn, unanticoagulated blood into clean glass tubes that were
kept at 37°C for 90 minutes. The serum was then promptly
separated by centrifugation and was frozen at —30°C until
assay. Serum TXB2 levels were measured by radioimmunoas-
say [361.
Urinary excretion of renal eicosanoids (TXB2, 6-keto-PGF1,,
and POE2, as a reflection of renal production of TXA2, PGI2
and PGE2, respectively) was determined in urine collected at
night (about 8 hrs) from subjects in the treatment group at each
time of examination. Eicosanoids were purified from urinary
matrix by extraction with ethyl acetate and chromatography on
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small columns of silicic acid [37]. The fraction containing TXB2,
6-keto-PGF1a and PGE2 was dried, resolubilized in buffer, and
aliquots corresponding to 125 ml of urine assayed by specific
radioimmunoassays [37, 38].
Serum (S) and urine (U, on 24 hr urine collection in duplicate
samples) creatinine were determined by standard colorimetric
methods, based on the development of color in alkaline envi-
ronment, in the presence of picric acid (Jaffé's reaction);
Creatinine clearance expressed in mI/mm was determined by
the standard formula
UxV
S
where V is urinary volume.
Urinary daily protein excretion (proteinuria) was measured
by the Red-Ponceau colorimetric method, and total serum
proteins by the biuret method; such measurements were carried
out in samples from three consecutive days for each time point
of the study; patients were carefully instructed about the
importance of a thorough 24 hour urine collection, crucial for all
urinary determinations. Short-term (day-to-day) variability of
the proteinuria measurement, as evaluated by the coefficient of
variation (mean SD) of the three replicates at each time point
of the study, was 8.7%. Long-term baseline variability of
proteinuria, as determined by the coefficient of variation of the
replicates in the five cases (4 patients) undergoing repeated
studies was 13.7%.
Serum albumin was estimated from a fractional analysis of
serum protein electrophoretogram (on standard paper electro-
phoresis).
Protein intake, in order to evaluate a possible spurious source
of proteinuria variability during the study, was evaluated cal-
culating the protein catabolic rate, as reflected by the Urea
Nitrogen Appearance rate. This was derived from the formula:
PCR = (UuN + 0.031 >< BW) X 6.25,
where PCR (protein catabolic rate) is the amount of degraded
protein per day, in g/day, UN is urinary urea nitrogen, in g,
and BW is body weight, in kg, as described [39]; measurements
of this parameter were obtained in triplicate for each point of
the study, and normalized for body weight.
Blood pressure measurements (standard Riva-Rocci sphyg-
momanometric method) were taken in duplicate on every day of
hospitalization by registered nurses, and averaged for each
phase of the study.
Statistical evaluation
Comparisons of all baseline values to post-treatment (week 6)
values were performed using the two-tailed Student's t-test for
paired values. Significance level was set at P < 0.05. For
proteinuria values, analysis of variance for repeated measures
was also performed. Results are expressed as mean SEM.
Results
All patients initially entered the trial successfully completed
the six weeks of treatment, with the exception of one who
decided to suspend the treatment because of gastric discomfort
and diarrhea after the intake of the first capsules. No other
week 0 week 6 week 10 week 16
Fig. 1. n-6 (D) and n-3 () PUFA, as percent of total plasma lipids in
patients treated with K-85. Analysis of variance for repeated measures
shows significant F values (P < 0.05), Student's t-test for paired values
indicates significant differences (P <0.01) in percent of both n-3 and n-6
PUFAs between week 0 and 6, and borderline significances (P < 0.07)
between week 0 and week 10, due to the limited number of observations
(N = 8 at weeks 0 and 6, and N = 3 at weeks 10 and 16).
patient reported any major adverse effect, including one patient
(LM) who had previously undergone partial gastrectomy be-
cause of peptic ulcer. A fishy aftertaste was, on the other hand,
commonly reported.
All patients, when specifically questioned, reported to have
had >90% intake of prescribed treatment capsules. This was
objectively reflected in laboratory analyses of n-3 PUFA incor-
poration into plasma lipids, reduction in triglycerides and
reduction in serum thromboxane.
The administration of n-3 PUFA as triglycerides (treatment
A) resulted in significant changes of the fatty acid profiles of the
n-3 and n-6 PUFA. The percentage levels of the n-3 PUFA in
plasma were increased sixfold for 20:5 (EPA) and 22:5 (docos-
apentaenoic acid, DPA) and twofold for 22:6 (DHA), respec-
tively, at the end of treatment. These fatty acids returned
practically to basal levels after four weeks of washout (week 10
of the study). Arachidonic acid, unchanged at the end of
treatment, was instead markedly reduced at the end of washout.
The percent of total fatty acids given by n-3 and n-6 PUFAs
during various phases of treatment B is shown in Figure 1. n-3
PUFA were about 2% at baseline, and increased to >7% at
week 6. This change was not sustained subsequently, being on
the average 3.3% at week 10. Reverse changes of n-6 PUFAs of
the same magnitude were observed; however percent of total
n-6 was still somewhat depressed at week 10, that is, four weeks
after drug discontinuation, despite total n-3 having already
returned to baseline by that time (Fig. 1). Interestingly, plasma
levels of EPA and DHA at the end of both types of treatment
were not statistically different, in spite of the higher dose of n-3
given as ethyl esters in treatment B.
Serum triglycerides consistently decreased in all patients
during treatment. Reduction was, on the average, 26% (NS) for
treatment A (not shown) and 28% for treatment B (P < 0.01;
Fig. 2). The decrease was more pronounced in patients exhib-
iting initially high triglycerides.
I
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P<o.01
I I
week 0 week 6
Fig. 2. Serum triglycerides in patients treated with K-85, at week 0 and
week 6. Mean and SEM of the observations at the two time points are
also shown.
Serum cholesterol also showed a minor reduction on the
average (from 274 27 mg/dl at week 0 to 252 24 mgldl at
week 6 for treatment B), which was of borderline significance (P
= 0.05) for the relatively high consistency among cases. HDL-
cholesterol did not change (42.3 3.6 mgldl at week 0; 41.2
4.7 at week 6 for treatment B). No significant change was
detected with the lower dose treatment (not shown).
As expected, there was a significant reduction in serum
thromboxane B2. This was about 30% in patients treated with
the high dose of n-3 FA (Fig. 3). A reduction of slightly lesser
magnitude (23%) occurred in patients treated with the low dose.
Bleeding time increased significantly. The increase was 21%
for treatment A (not shown) and 33% for treatment B (P < 0.01)
(Fig. 4).
Urinary thromboxane B2 excretion (as a reflection of renal
8-
E
a,
E
"a,
4-
TXA2 production) and urinary 6-keto-PGF1a excretion (as a
reflection of renal PGI2 production) were both similarly reduced
by the ethyl ester treatment (for TXB2: 7.8 1.7 ng/hr at week
0; 4.4 0.6 nglhr at week 6, P = 0.06; for 6-keto-PGF1a: 24.3
5.1 nglhr at week 0; 15.2 2.8 nglhr at week 6, P 0.09). A
similar reduction also occurred for urinary PGE2. Urinary
eicosanoids were quickly back at baseline values already at
week 10 (for urinary TXB2: 8.4 4.8 nglhr) at week 10.
Treatment with low-dose triglycerides was not associated,
however, with any directional trend towards the reduction (not
shown).
No significant changes were seen throughout the study for
serum creatinine and serum albumin (data not shown). Creati-
nine clearance was 97 8 ml/min and 113 8 mllmin at weeks
0 and 6, respectively, for treatment A (NS); 104 12 mI/mm
and 103 12 mllmin at weeks 0 and 6, respectively, for
treatment B (NS).
For both regimens some reduction in proteinuria was ob-
served concomitantly with fish oil treatment. This was marginal
for the low-dose treatment (from 3.8 0.6 g/24 hr to 3.3 0.9
g/24 hr, P = NS), but significant for the high-dose treatment
(from 4.1 1.1 g/24 hr to 2.9 0.8 g/24 hr, P <0.05; Fig. 5).
This reduction was sustained, at week 10 and 18, and returned
towards baseline values only at week 27 (Fig. 6). The one
subject who received K-85 treatment twice showed smi1ar
reductions in proteinuria on both occasions (28% and 33% after
the first and the second course of treatment, respectively).
Daily protein intake, as evaluated by the urea nitrogen
appearance rate was remarkably stable throughout the study,
being 1.100 0.03 and 1.080 0.04 glkglday before and after
the triglyceride treatment, and 1.042 0.03 and 1.043 0.04
g/kg/day before and after the ethyl ester treatment, respec-
tively, therefore not accounting for changes in proteinuria.
Some reduction in blood pressure was observed only with the
higher dose regimen: during treatment B systolic blood pressure
decreased from 143 4 to 134.5 3 mm Hg (P = NS) and
800 -
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200 -I
10 -
P<0.01
2-
P<0.05
week 0 week 6
Fig. 4. Bleeding time in patients treated with K-85, at week 0 and week
6. Mean and SEM of the observations at the two time points are also
shown.
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600 -
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week 0 week 6
Fig. 3. Serum thromboxane B2 in patients treated with K-85, at week 0
and week 6. Mean and SEM of the observations at the two time points
are also shown.
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diastolic blood pressure from 90 2.4 to 85 2.1 (P < 0.05, for
the higher consistency among cases). No change occurred, on
the other hand, in patients treated with the low-dose triglycer-
ide regimen (from 132.5 7.5 to 136.3 11mm Hg for systolic
blood pressure; from 75 7 to 55 5 mm Hg for diastolic blood
pressure). In the high-dose treatment group, however, changes
in proteinuria were apparently unrelated to changes in blood
pressure: at linear regression analysis, correlation coefficient (r)
was 0.23 for systolic and 0.08 for diastolic blood pressure,
respectively (for both P = NS). Reduction in blood pressure at
least additive to that of calcium antagonist therapy (nitren-
dipine) was observed in patient MM with the high-dose regi-
men.
No difference in results in relationship with histology (mem-
branous glomerulonephritis versus focal glomerular sclerosis)
was observed.
Discussion
This study shows that, in patients with chronic glomerular
disease, two different dose regimens of n-3 PUFAs may reduce
proteinuria, and the high dose regimen did it to a statistically
significant extent. The present study is, to the best of our
knowledge, the first report of beneficial effects of n-3 FA
supplementation in this patient category; however, it confirms a
number of previous observations in experimental animals [17—
29], mostly suggestive of a beneficial effect.
Patient compliance to treatment was monitored by question-
ing and, more objectively, by laboratory measurements of
incorporation of n-3 FA in plasma phospholipids, monitoring of
serum lipids and of serum TXB2. Both treatment regimens used
resulted in a significant increase in n-3 FA, as percentage of
total plasma fatty acids, and in a corresponding decrease in the
percentage of n-6 FA. The very consistent decreases in triglyc-
erides and serum TXB2, observed in the vast majority of our
patients, confirm previous findings in healthy volunteers and
non-renal patients, and extend them to a situation of chronic
glomerular disease in which such changes might exert, by
themselves, beneficial effects [40—43]. Also, the increase in
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MaxEPA 12 c/day Time, weeks
bleeding time by fish oil, which we report in the present study,
is consistent with previously reported data in other patient
categories. This effect highlights the influence of fish oil on
platelet-vessel wall interactions, one potential mechanism of
improvement of renal function by fish oil [44].
Spontaneous variations of proteinuria during the course of
renal disease are an obvious potential cause for false positive
findings. However, the coefficient of variation of proteinuria
during treatment was almost double than the one reflecting the
long-term variability of proteinuria measurements in baseline
conditions in the same patients, pointing to a specific effect of
the treatment. Also, variations in proteinuria observed through-
out this study could certainly not be accounted for by variation
of protein intake, which remained remarkably stable. Also the
time course of proteinuria suggests a time relationship with the
treatment.
Changes in blood pressure are, in addition to favorable effects
P=0.031
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Fig. 5. Proteinuria in patients treated with K-85, at week 0 and week 6.
Mean and SEM of the observations at the two time points are also
shown.
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Fig. 6. Time course of proteinuria in the 7 patients (3 on MaxEPA, 4 on
K-85) who were followed up to the 27th week (21 weeks after drug
discontinuation).
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on hemostasis, a potential mechanism by which n-3 FA may
ameliorate proteinuria. These compounds have indeed been
shown, in at least two prospective double-blind randomized
trials, to reduce blood pressure in essential hypertension [10,
11]. A trend towards blood pressure reduction was indeed
evident for the high-dose treatment also in our study. However
the relationships of the blood pressure changes to the amelio-
ration of proteinuria are not clear and certainly need further
investigation. In our limited series of observations no relation-
ship was found between the decrease in blood pressure and the
decrease in proteinuria. It may also be pointed out that for only
some antihypertensive agents (mostly some ACE inhibitors)
there have been reports of beneficial effects on proteinuria (see
below). Finally, n-3 FA may be additive or synergistic to
antihypertensive medications in reducing blood pressure [45],
but nothing is known about the potential additive or synergistic
effect on other correlates of blood pressure such as proteinuria
in patients with renal disease.
In terms of metabolism of n-3 PUPAs, it is especially
noteworthy that the decrease in proteinuria in our series ap-
pears sustained for some 12 weeks after discontinuation of
treatment. Only during the treatment period did the low pro-
teinuria levels correspond well with the levels of EPA and DHA
in plasma lipids. The effects on proteinuria were even more
pronounced after discontinuation of treatment, whereas this
was not reflected by EPA and DHA levels in plasma lipids. The
time course of effects on proteinuria is indeed quite similar to
the time course of reduction observed for interleukin-1, 2 and
tumor necrosis factor [14, 15], another well-documented effect
of n-3 FA for which there appears to be a dissociation from
estimates of incorporation. This suggests, on the one hand, that
n-3 FA effects require saturation of intracellular lipid compart-
ments, which may only loosely reflected by the crude estimate of
incorporation of n-3 PUFAs into plasma lipids or total cellular
lipids; on the other hand, it suggests different time courses for
different effects, some of which may reflect only very remotely
the actual intake period of fish oil.
Treatment with n-3 FA was associated with a clear-cut
reduction in both serum and urinary thromboxane, a reflection
of platelet and renal production of thromboxane, respectively
[38]. Theoretically, the reduction in renal thromboxane produc-
tion may be linked mechanistically to the observed reduction in
proteinuria [46]. However, the reduction in thromboxane pro-
duction was transient, being already back to pre-treatment
values four weeks after the discontinuation of treatment, and
therefore correlating only partially with the time course of
proteinuria reduction. Further, and in keeping with previously
reported data [47], n-3 PUPAs reduced also both urinary POE2
and P012. This last effect could therefore potentially counter-
balance the potential benefit exerted by the reduction in renal
thromboxane, and actually reduce the renal vasodilatory re-
serve in an already diseased kidney. Detrimental effects due to
the reduction of vasodilatory prostanoids have been demon-
strated for non-steroidal antiinflammatory drugs due, at least in
part, to their massive reduction of POE2 and POT2 [48]. How-
ever, in the case of n-3 PUPAs, POE2 and POT2 reductions
appear much less dramatic than with NSAIDs. Also, with n-3
PUFAs, POT3 [5] and POE3 [49] are alternatively formed. The
antibodies used in our assays certainly cross-reacted to some
extent with the POT3 derivative (about 20%), and, likely, with
POE3. However, these assays certainly underestimated the
amounts of P013 and POE3 produced. Although the vasodila-
tory properties of POT3 are well known, much less is known
about the potential vasodilatory effects of POE3; furthermore,
their effects on kidney physiology and pathophysiology are not
well understood. Indirectly, data on renal plasma flow and
glomerular filtration rates in other human studies indicate that
there can be improvement in these clinical indicators, and thus
no deterioration of the renal vasodilatory reserve in patients
with chronic kidney diseases who take n-3 PUPA [50].
Additionally, other effects, not measured in this trial, could
have contributed to the clinical improvement observed. Among
them are possible immunomodulatory effects due to depression
of interleukins 1 and 2 and tumor necrosis factor [14, 15],
antiproliferative effects, due to decrease in production of
growth factors [16], possibly contributing to mesangial prolifer-
ative phenomena, and effects on the filtrability of macromole-
cules [51].
Our study did not show directional changes in other param-
eters of renal function, such as creatinine and creatinine clear-
ance. This could be noteworthy in view of the fact that another
drug category, ACE inhibitors, have also been shown to reduce
proteinuria in similar patients, probably altering intraglomerular
hemodynamics by different effects on the tone of the afferent
versus the efferent arteriole [52]. The counterpart of this effect,
for this drug category, is a detrimental and potentially danger-
ous increase in serum creatinine and a decrease in glomerular
filtration rate. Whatever the mechanism of fish oil in affecting
proteinuria may be, such mechanism has to be different from
that of ACE inhibitors.
Most parameters showing changes concomitant with treat-
ment, namely proteinuria, serum thromboxane, urinary throm-
boxane and prostacyclin, and serum triglycerides, showed more
changes with the higher than with the lower dose treatment,
suggesting the existence of a dose-effect relationship. This was
not so, however, for changes in the incorporation in plasma
lipids. The reason for this is uncertain, but may reflect, gain, the
partitioning of long-chain fatty acids into functionally different
intracellular pools, not reflected by the relatively crude estimate
of total plasma lipids (refer to previous text).
Limitations of our study are the lack of a placebo control and
the relatively small number of patients studied. A parallel-
group, placebo-controlled study would have required many
more subjects, and a crossover design was partially precluded
by the long-term carryover effects of fish oil on many biological
parameters, including, possibly, proteinuria. The relatively
prolonged follow-up of some of our patients, and the reproduc-
ibility of proteinuria measurements both in the short-term and
in the long-term in baseline conditions, in our series, reinforce
our conclusions about beneficial effects on proteinuria. Because
of these limitations, however, a larger study including more
patients appears opportune, and is currently being planned; the
influence of long-term supplementation must still also be deter-
mined in this group of patients.
In conclusion, high-dose n-3 PUPA for six weeks reduced
proteinuria in non-dialyzed patients with chronic glomerular
diseases. This effect was observed for up to 12 weeks after
discontinuation of treatment and returned to baseline by week
21 after stopping therapy. Our observations indicate a potential
therapeutic benefit of n-3 PUPA for patients with renal disease,
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with an improvement of kidney function. Further investigations
on long-term supplementation periods in more such patients are
merited. The very favorable safety profile of these natural
substances should stimulate further trials of n-3 PUFA as an
adjuvant treatment for chronic glomerular disease.
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